Kidswell Bio Corporation Reports Earnings Results for the Half Year Ended September 30, 2021
November 05, 2021 at 02:30 am EDT
Share
Kidswell Bio Corporation reported earnings results for the half year ended September 30, 2021. For the half year, the company reported sales was JPY 740.64 million compared to JPY 174.49 million a year ago. Net loss was JPY 463.22 million compared to JPY 696.08 million a year ago. Basic loss per share from continuing operations was JPY 15.3 compared to JPY 24.49 a year ago.
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
KIDSWELL BIO CORPORATION 
